id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-282825-svgknqud	Ramaswamy, Swathi Beladakere	COVID-19 in Refractory Myasthenia Gravis- A Case Report of Successful Outcome	2020-06-02		.txt	text/plain	1745	108	41	This is a brief report of a patient who has refractory Myasthenia Gravis, on multiple long-term immunosuppressive therapies and contracted COVID-19 during this 2020 pandemic. This case report describes myasthenic patient who was infected COVID-19 and recovered without myasthenic crisis/exacerbation, and no COVID-19 complications despite chronic immunomodulatory therapy. MG is treatable with immunomodulation from long-term immunosuppressive drugs, IV immunoglobulin (IVIg), and plasmapheresis [1] [2] [3] In approximately 15% of patients, severe weakness of respiratory muscles causes restrictive respiratory failure (ie, myasthenic crisis), a true neurologic emergency that requires prompt treatment in an intensive care setting [1] [2] [3] [4] [5] [6] [7] [8] . In the recent global pandemic from novel coronavirus (COVID-19/SARS-CoV2), myasthenic patients can be considered high risk in case of chronic immunosuppression and in case of respiratory muscle weakness [11] [12] [13] [14] .	./cache/cord-282825-svgknqud.txt	./txt/cord-282825-svgknqud.txt